Free Trial
→ Silicon Valley Gold Rush (From Stansberry Research) (Ad)
NASDAQ:SNPX

Synaptogenix 5/15/2023 Earnings Report

Synaptogenix logo
$2.40 -0.03 (-1.03%)
Closing price 03:58 PM Eastern
Extended Trading
$2.28 -0.12 (-4.97%)
As of 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Synaptogenix EPS Results

Actual EPS
-$6.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Date
5/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Synaptogenix's next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

Synaptogenix Earnings Headlines

Synaptogenix Inc Ordinary Shares
January 3, 2025 | morningstar.com
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
December 20, 2024 | prnewswire.com
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
May 5, 2025 | Stansberry Research (Ad)
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary
October 7, 2024 | benzinga.com
Synaptogenix secures $5 million in preferred stock financing
September 13, 2024 | investing.com
Synaptogenix Announces $5.0 Million Financing
September 11, 2024 | prnewswire.com
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles